Kimera receives IND approval to study mesenchymal stem cell exosomes to treat COVID-19

May 17, 2023

Kimera Labs Inc. has received IND approval from the FDA to study the company’s exosomes in a phase I/IIa trial, which is set to begin next month.

BioWorld Science Infection Coronavirus FDA IND

Today's news in brief

BioWorld

BioWorld briefs for Sept. 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Sept. 10, 2025.

Neuronal lipid metabolism plays role in ABCA7 Alzheimer’s risk

BioWorld Science

Loss of function variants in the lipid transporter gene ATP-binding cassette ABC transporter A7 (ABCA7) nearly double the risk of developing Alzheimer’s disease...

Boston Sci acquires Elutia's bioenvelopes for $88M

BioWorld MedTech

Elutia Inc. agreed to sell its Elupro and Cangaroo bioenvelopes for implantable medical devices to Boston Scientific Corp. for $88 million in cash. Elutia will...

Pharmaengine’s PEP-08 gains trial clearances for solid tumors

BioWorld Science

Xtalpi Inc. has announced regulatory clearances in Australia and Taiwan for phase I trials of PEP-08, a next-generation PRMT5 inhibitor candidate developed under...